




Theranexus

SHIFTING THE LINES AGAINST
CENTRAL NERVOUS SYSTEM
DISORDERS



Theranexus Announces a New European Patent Protecting THN201, Its Drug Candidate for the Treatment of Neurocognitive Disorders Including Those Associated with Alzheimers

Lyon, 9 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that it has received a European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers.

The patent was granted to the Alternative Energies and Atomic Energy Commission (CEA) by the European Patent Office (EPO). Theranexus enjoys an exclusive worldwide license for the patent.

This patent on THN201 numbered EP2773337, whose inventors are Franck Mouthon (CEO) and Mathieu Charvériat (CSO), is entitled *“Use of Anti-Connexin Agents for Enhancing the Therapeutic Effect of Acetylcholinesterase Inhibitors”*. It protects THN201, which combines an anti-connexin agent, such as mefloquine, and donepezil as a psychotropic drug, until 2032 (initial protection without a “Supplementary Protection Certificate” (SPC)).

“Several days after receiving the regulatory authorisation to launch the stage 1b clinical trial on the neurocognitive disorders in Alzheimer’s disease¹, the results of which are expected in late 2019,” says Theranexus Chairman and CEO Franck Mouthon, “we’re very happy to have obtained this new European patent protecting THN201. Theranexus strengthens the value of its drug candidate THN201 and its portfolio of innovative products THN102, THN201 and THN101. Getting a comprehensive set of claims having both ‘product’ and ‘therapeutic use’ claims for THN 201 is an integral part of our intellectual property strategy.”

About THN201 in neurocognitive disorders in Alzheimer's disease

THN201 is a drug candidate for the treatment of cognitive disorders in Alzheimer's disease that is entering research Phase Ib. The drug candidate THN201 is a combination of donepezil (which affects neuronal activity), and mefloquine (which affects glial cell activity). It has already demonstrated in preclinical studies a superior pharmacological efficacy than the reference treatment, as well as an excellent safety profile.

Alzheimer's disease (AD) causes the slow degeneration of neurons which it is characterised by short-term memory loss, impairment of some bodily functions and can cause spatial disorientation. Patients gradually lose their cognitive abilities and independence. Such neurocognitive disorders are particularly challenging, not only for patients but also for caregivers and families.

Today, many diseases characterised by neurocognitive disorders remain an economic burden and the cause of some significant unmet medical needs. Health costs associated with neurocognitive disorders estimated at more than \$640 billion worldwide, driven by institutionalization, continue to increase dramatically. Today, it is estimated that more than 45 million people worldwide have neurocognitive disorders. A number expected to reach 75 million by 2030.

ABOUT THERANEXUS

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body’s response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.

The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

More information at: www.theranexus.com



Contacts

THERANEXUS

Thierry Lambert

Financial and Administrative Director

investisseurs@theranexus.fr

ACTUS finance & communication

Caroline Lesage / Théo Martin

Investor Relations

+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75

theranexus@actus.fr

FP2COM

Florence Portejoie

Media Relations

+ 33 (0)6 07 76 82 83

fportejoie@fp2com.fr